<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193801</url>
  </required_header>
  <id_info>
    <org_study_id>2015-08 MVIV</org_study_id>
    <nct_id>NCT03193801</nct_id>
  </id_info>
  <brief_title>PARTNER 3 Trial - Mitral Valve in Valve</brief_title>
  <official_title>PARTNER 3 Trial - SAPIEN 3 Transcatheter Heart Valve Implantation in Patients With a Failing Mitral Bioprosthetic Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients&#xD;
      with a failing mitral bioprosthetic valve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-arm, multicenter clinical trial. This study will enroll patients with&#xD;
      symptomatic heart disease due to a failing bioprosthetic mitral valve (stenosed,&#xD;
      insufficient, or combined).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">September 2031</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Effectiveness - composite of all-cause mortality and stroke</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>30 Days</time_frame>
    <description>NYHA is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>30 days</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom, social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation</measure>
    <time_frame>30 days</time_frame>
    <description>Echocardiographic assessment of the degree of mitral valve regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary artery systolic pressure</measure>
    <time_frame>30 days</time_frame>
    <description>Echocardiographic assessment of pulmonary artery systolic pressure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Failing mitral transcatheter valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards SAPIEN 3 transcatheter valve, Model 9600TFX</intervention_name>
    <description>Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.</description>
    <arm_group_label>Failing mitral transcatheter valve</arm_group_label>
    <other_name>TMVR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Failing surgically implanted bioprosthetic valve in the mitral position demonstrating&#xD;
             ≥ moderate stenosis and/or ≥ moderate insufficiency.&#xD;
&#xD;
          2. Surgical bioprosthetic valve with a true internal diameter (True ID) of 16.5 mm to&#xD;
             28.5 mm.&#xD;
&#xD;
          3. NYHA Functional Class ≥ II.&#xD;
&#xD;
          4. Heart Team agrees the patient is intermediate risk (i.e. STS score of ≥3 and &lt; 8).&#xD;
&#xD;
          5. Heart Team agrees valve implantation will likely benefit the patient.&#xD;
&#xD;
          6. The study patient has been informed of the nature of the study, agrees to its&#xD;
             provisions and has provided written informed consent as approved by the Institutional&#xD;
             Review Board (IRB) / Ethics Committee (EC) of the respective clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Index valve has ≥ mild paravalvular regurgitation where the surgical bioprosthesis is&#xD;
             not securely fixed in the native annulus or is not structurally intact as determined&#xD;
             by transesophageal echocardiography (TEE).&#xD;
&#xD;
          2. Surgical or transcatheter aortic valve placed so that extension into left ventricular&#xD;
             outflow tract (LVOT) that may impinge on the mitral implant.&#xD;
&#xD;
          3. Known residual mean gradient &gt;10 mmHg at the end of the index procedure for&#xD;
             implantation of the original surgical valve.&#xD;
&#xD;
          4. Severe right ventricle (RV) dysfunction.&#xD;
&#xD;
          5. Anatomical characteristics that would preclude safe access to the apex (transapical).&#xD;
&#xD;
          6. Severe regurgitation or stenosis of any other valve.&#xD;
&#xD;
          7. Severe lung disease (FEV1 &lt; 50% predicted) or currently on home oxygen&#xD;
&#xD;
          8. Severe pulmonary hypertension (e.g., PA systolic pressure ≥ 2/3 systemic pressure)&#xD;
&#xD;
          9. Anatomical characteristics that would increase risk of LVOT obstruction (e.g.,&#xD;
             aortomitral angle, LVOT size, etc.).&#xD;
&#xD;
         10. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before enrollment.&#xD;
&#xD;
         11. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is&#xD;
             performed within 30 days prior to the index procedure. Implantation of a permanent&#xD;
             pacemaker (PPM) or implantable cardioverter defibrillator (ICD) is not considered an&#xD;
             exclusion.&#xD;
&#xD;
         12. Patients with planned concomitant surgical or transcatheter ablation for atrial&#xD;
             fibrillation.&#xD;
&#xD;
         13. Leukopenia (white blood count &lt; 3000 cell/mL), anemia (hemoglobin &lt; 9 g/dL),&#xD;
             thrombocytopenia (blood platelet count &lt; 50,000 cell/mL), history of bleeding&#xD;
             diathesis or coagulopathy, or hypercoagulable states.&#xD;
&#xD;
         14. Untreated clinically significant coronary artery disease requiring revascularization.&#xD;
&#xD;
         15. Hemodynamic or respiratory instability requiring inotropic support, mechanical&#xD;
             ventilation, or mechanical heart assistance within 30 days of enrollment.&#xD;
&#xD;
         16. Emergency intervention/surgical procedures within one month (30 days) prior to the&#xD;
             procedure.&#xD;
&#xD;
         17. Any planned surgical, percutaneous coronary, or peripheral procedure to be performed&#xD;
             within the 30-day follow-up from the procedure.&#xD;
&#xD;
         18. Hypertrophic cardiomyopathy with obstruction (HOCM).&#xD;
&#xD;
         19. Left ventricular ejection fraction (LVEF) &lt; 30%.&#xD;
&#xD;
         20. Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation.&#xD;
&#xD;
         21. Inability to tolerate or condition precluding treatment with&#xD;
             antithrombotic/anticoagulation therapy during or after the valve implant procedure.&#xD;
&#xD;
         22. Absolute contraindications or allergy to iodinated contrast that cannot be adequately&#xD;
             treated with premedication.&#xD;
&#xD;
         23. Stroke or transient ischemic attack (TIA) within 90 days of enrollment.&#xD;
&#xD;
         24. Symptomatic carotid or vertebral artery disease or successful treatment of carotid&#xD;
             stenosis within 30 days of enrollment.&#xD;
&#xD;
         25. Renal insufficiency (eGFR &lt; 30 ml/min per the Cockcroft-Gault formula) and/or renal&#xD;
             replacement therapy at the time of screening.&#xD;
&#xD;
         26. Active bacterial endocarditis within 6 months (180 days) of the procedure.&#xD;
&#xD;
         27. Patient refuses blood products.&#xD;
&#xD;
         28. Estimated life expectancy &lt; 24 months.&#xD;
&#xD;
         29. Currently participating in an investigational drug or another device study. Note:&#xD;
             Clinical trials requiring extended follow-up for products that were investigational,&#xD;
             but have since become commercially available, are not considered investigational&#xD;
             trials.&#xD;
&#xD;
         30. Positive urine or serum pregnancy test in female subjects of childbearing potential.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayra Guerrero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris S. Malaisrie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Zajarias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore University Health System Research Institution</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital/ Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center/ Atlantic Health System Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Lagone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/ New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Heart &amp; Vascular Institution</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Sciences Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital of Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração da Universidade de São Paulo</name>
      <address>
        <city>Cerqueira César</city>
        <state>São Paulo</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Vila Mariana</city>
        <state>São Paulo</state>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAPIEN 3</keyword>
  <keyword>PARTNER 3</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>TMVR</keyword>
  <keyword>failing valve</keyword>
  <keyword>failing bioprosthetic valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

